Fiorillo, M., Scatena, C., Naccarato, A. G., Sotgia, F., & Lisanti, M. P. (2021). Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase. Cell death and differentiation, 28(9), 2797-2817. https://doi.org/10.1038/s41418-021-00788-x
Chicago-Zitierstil (17. Ausg.)Fiorillo, Marco, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, und Michael P. Lisanti. "Bedaquiline, an FDA-approved Drug, Inhibits Mitochondrial ATP Production and Metastasis in Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase." Cell Death and Differentiation 28, no. 9 (2021): 2797-2817. https://doi.org/10.1038/s41418-021-00788-x.
MLA-Zitierstil (9. Ausg.)Fiorillo, Marco, et al. "Bedaquiline, an FDA-approved Drug, Inhibits Mitochondrial ATP Production and Metastasis in Vivo, by Targeting the Gamma Subunit (ATP5F1C) of the ATP Synthase." Cell Death and Differentiation, vol. 28, no. 9, 2021, pp. 2797-2817, https://doi.org/10.1038/s41418-021-00788-x.